A5024071137- SARS-CoV-2 and COVID-19 Research
- Viral Infections and Outbreaks Research
- Animal Virus Infections Studies
- COVID-19 Clinical Research Studies
- Respiratory viral infections research
- Hepatitis B Virus Studies
- Monoclonal and Polyclonal Antibodies Research
- Long-Term Effects of COVID-19
- Immunotherapy and Immune Responses
- COVID-19 and Mental Health
- Pneumonia and Respiratory Infections
- Viral Infections and Vectors
- Viral gastroenteritis research and epidemiology
- Acute Myocardial Infarction Research
- Renal Diseases and Glomerulopathies
- SARS-CoV-2 detection and testing
- CAR-T cell therapy research
- Infection Control and Ventilation
- Cardiovascular Effects of Exercise
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Complement system in diseases
- Parasitic infections in humans and animals
- Health and Medical Studies
- Antibiotic Use and Resistance
- HIV-related health complications and treatments
Universität Hamburg
2016-2024
University Medical Center Hamburg-Eppendorf
2020-2024
German Center for Infection Research
2020-2024
Klinikum Itzehoe
2024
Bernhard Nocht Institute for Tropical Medicine
2016-2023
Martini-Klinik
2021
Hypertension Institute
2013
The Middle East respiratory syndrome coronavirus (MERS-CoV) causes a disease with case fatality rate of up to 35%. Given its potential cause public health emergency and the absence efficacious drugs or vaccines, MERS is one WHO priority diseases warranting urgent research development countermeasures. We aimed assess safety tolerability an anti-MERS-CoV modified vaccinia virus Ankara (MVA)-based vaccine candidate that expresses MERS-CoV spike glycoprotein, MVA-MERS-S, in healthy adults.
Abstract SARS-CoV-2 is the causative agent of COVID-19 and a severe threat to global health. Patients infected with show wide range symptoms disease severity, while limited data available on its immunogenicity. Here, kinetics development SARS-CoV-2-specific antibody responses in relation clinical features dynamics specific B-cell populations are reported. Immunophenotyping B cells was performed by flow cytometry longitudinally collected PBMCs. In parallel, serum samples were analyzed for...
The Middle East respiratory syndrome (MERS) is a disease caused by MERS coronavirus (MERS-CoV). In follow up to phase 1 trial, we perform longitudinal analysis of immune responses following immunization with the modified vaccinia virus Ankara (MVA)-based vaccine MVA-MERS-S encoding MERS-CoV-spike protein. Three homologous immunizations were administered on days 0 and 28 late booster vaccination at 12 ± 4 months. Antibody isotypes, subclasses, neutralization capacity as well T B cell...
The current COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). A better understanding of its immunogenicity can be important for development improved diagnostics, therapeutics, and vaccines. Here, we report longitudinal analysis three patients with moderate (#1) mild disease (#2 #3). Antibody serum responses were analyzed using spike glycoprotein enzyme linked immunosorbent assay (ELISA), full-proteome peptide, glycan microarrays. ELISA...
Vaccine development is essential for pandemic preparedness. We previously conducted a Phase 1 clinical trial of the vector vaccine candidate MVA-MERS-S against Middle East respiratory syndrome coronavirus (MERS-CoV), expressing its full spike glycoprotein (MERS-CoV-S), as homologous two-dose regimen (Days 0 and 28). Here, we evaluate safety (primary objective) immunogenicity (secondary exploratory objectives: magnitude characterization vaccine-induced humoral responses) third vaccination...
The last seven years have seen the greatest surge of Ebola virus disease (EVD) cases in equatorial Africa, including 2013–2016 epidemic West Africa and recent epidemics Democratic Republic Congo (DRC). vaccine clinical trials that took place DRC, as well follow-up studies collaboration with EVD survivor communities, for first time allowed researchers to compare immune memory induced by natural infection vaccination. These comparisons may be relevant evaluate putative effectiveness vaccines...
Lassa fever is endemic in large parts of West Africa. The recommended antiviral treatment ribavirin. Two regimens are currently endorsed Nigeria: the "McCormick regimen" based on a study published 1986 and "Irrua constituting simplified schedule developed at Irrua Specialist Teaching Hospital, Nigeria. Evidence for safety efficacy ribavirin patients poor pharmacokinetic data both lacking.
Besides neutralizing antibodies, which are considered an important measure for vaccine immunogenicity, Fc-mediated antibody functions can contribute to antibody-mediated protection. They strongly influenced by structural properties such as subclass and Fc glycan composition. We here applied a systems serology approach dissect humoral immune responses induced MVA-MERS-S, MVA-vectored against the Middle East respiratory syndrome coronavirus (MERS-CoV). Building on preceding studies reporting...
Emerging or re-emerging viral diseases have a pandemic potential and threaten global health. Vaccination is of crucial importance in the prevention emerging diseases.
Taenia martis , a tapeworm harbored in the intestine of mustelids, is rarely encountered zoonotic cysticercosis pathogen. The larval stage closely resembles solium cysticercus, but natural host and thus epidemiology disease different. We here report human eye infection diagnosed molecularly previously healthy female German patient. case represents third described worldwide; two previous cases were also European, involving brain.
<b><i>Background:</i></b> Antibody (Ab)-dependent cellular cytotoxicity (ADCC) is considered to be a relevant mechanism of action Ab-based tumor therapies. However, knowledge about ADCC capacity dialysis patients (DP) limited. The aim our study was investigate if effector cells obtained from DP differed those healthy individuals (HI). <b><i>Methods:</i></b> First, we performed assays with isolated polymorphonuclear (PMN) and peripheral blood...
Introduction Lassa fever (LF) is a severe and often fatal systemic disease in humans affects large number of countries West Africa. Treatment options are limited to supportive care the broad-spectrum antiviral agent ribavirin. However, evidence for ribavirin efficacy patients with LF poor pharmacokinetic (PK) data not available. Irrua Specialist Teaching Hospital (ISTH) developed an intravenous regimen different WHO recommendation. Apart from lower total daily dose drug usually administered...
International travel has been identified as a major contributing factor to the global spread of MRSA. We examined incidence MRSA-colonization in cohort 196 travellers. observed low rate only one case MRSA, indicating risk acquisition travel.
Licensed vaccines against the Middle East respiratory syndrome coronavirus (MERS-CoV), an emerging pathogen of concern, are lacking. The modified vaccinia virus Ankara vector-based vaccine MVA-MERS-S, expressing MERS-CoV-spike glycoprotein (MERS-S), is one 3 candidate in clinical development and elicits robust humoral cellular immunity. Here, we identified for first time a MERS-S-specific CD8+ T-cell epitope HLA-A*03:01/HLA-B*35:01-positive vaccinee using screening assay, intracellular...
Was ist neu? Pathologie und Bedeutung der Grundlagenforschung 60 Jahre nach einer katastrophalen RSV-Impfstoffstudie mit Todesfällen bei Kindern erleben wir momentan eine rasant positive Entwicklung 3 zugelassenen Impfstoffen gegen RSV Personen >60 Jahre. Die spielte auch entscheidende Rolle in Impfstoff-Entwicklung SARS-CoV-2. Neue RSV-Impfstoffe Im Jahr 2023 erhielten innerhalb von wenigen Wochen gleich 2 äußerst ähnliche, proteinbasierte Impfstoffe die Zulassung Europäischen...
Abstract Purpose Bacterial pneumonia, a major cause of respiratory tract infections (RTI), can be challenging to diagnose and treat adequately, especially when seasonal viral pathogens co-circulate. The aim this study was give real-world snapshot the burden disease treatment choices in emergency department (ED) tertiary care hospital Germany fall 2022. Methods Anonymized analysis quality control initiative that prospectively documented all patients presenting our ED with symptoms suggestive...